Expression of VEGF in kidney of diabetic rats

Journal of Sichuan University (Medical Science)

Volumn 38, Issue 4, 2007, Pages 633-636

  Chen, Ze jun ^a   Yang, Yi bin ^a   Huang, Song min ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; VEGF

Indexed keywords

EID: 34547410305     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Flyvbjerb A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia, 2000;43(10):1205-1223.
2. Gudehithlu KP, Singh AK. Vascular endothelial growth factor and diabetic nephropathy. Int J Artif Organs, 1999;22(5):297-299.
3. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosin kinases Tie-1 and Tie-2 in blood vessel formation. Nature, 1995;376(6535):70-74.
4. Io H, Hamada C, Ro Y, et al. Morphology changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int, 2004;65(5):1927-1936.
5. De Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol, 2001;12(5):993-1000.
6. Simon M, Grone HJ, Johren O, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol, 1995;268(2 Pt 2):F240-F250.
7. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem, 2003;278(15):12605-12608.
8. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase-1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest, 2003;11(5):649-658.
9. Williams B, Gallacher B, Patel H, et al. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes, 1997;46(9):1497-1503.
10. Satchell SC, Anderson KL, Mathieson PW. Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol, 2004;15(3):566-574.
11. Yamamoto Y, Maeshima Y, Kitayama H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes, 2004;53(7):1831-1840.
12. Senthil D, Choudhury GG, McLaurin C, et al. Vascular endothelial growth factor induces protein synthesis in renal epithelialcells: a potential role in diabetic nephropathy. Kidney Int, 2003;64(2):468-479.